Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04673266 · ClinicalTrials.gov registry record · Phase 2
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
A Phase 2 study of Thrombocytopenia and Lymphoma Patients, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 8
- Study locations
NCT04673266: Active Phase 2 study of Thrombocytopenia and Lymphoma Patients, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04673266 is a Phase 2 study of Thrombocytopenia and Lymphoma Patients that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 11 participants, below the 311-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04673266, a Phase 2 study of Thrombocytopenia and Lymphoma Patients, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfusions. In addition, we will determine how safe it is to give romiplostim to people with lymphoma who have low platelet count from chemotherapy.
Primary Outcome
defined as PLT \< 50,000 cells/mcl) at the end of cycle 1 (C1D21±2d); presence of grade 4 thrombocytopenia (\<25,000 cells/mcl) at any time throughout the treatment cycle; or indication for a PLT transfusion for thrombocytopenia or for bleeding at any time throughout the treatment cycle.
Conditions Studied
Interventions
- DRUG Romiplostim
Study Locations (8)
New York
- Memorial Sloan Kettering Commack (All Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (All Protocol Activites) - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT04673266 still lists
NCT04673266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 311-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Romiplostim is the first listed.
NCT04673266 lists 8 locations in 3 states (New York, New Jersey, Florida).
Frequently Asked Questions
What is clinical trial NCT04673266 about?
NCT04673266 is a clinical study titled "Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma". The purpose of this study is to see if the study drug, romiplostim, helps low platelet count caused by standard chemotherapy treatment for lymphoma. This study will also look at whether romiplostim can prevent the need for chemotherapy dose delays, chemotherapy dose reductions, and platelet transfus...
What is the current status of trial NCT04673266?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-12-14. Estimated completion is 2026-12.
What conditions does trial NCT04673266 study?
This clinical trial studies the following conditions: Thrombocytopenia, Lymphoma Patients.
What interventions are being tested in trial NCT04673266?
The interventions under investigation include: Romiplostim (DRUG).
Who is sponsoring clinical trial NCT04673266?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04673266 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04673266's enrollment target sits among peer trials
11 20th of 20 higher than 1 of 20 other Thrombocytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
COMPLETED · Phase 2
-
Daclizumab to Treat Chronic Immune Thrombocytopenia
COMPLETED · Phase 2
-
Eltrombopag for Post Transplant Thrombocytopenia
COMPLETED · Phase 2
-
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI